anetumab ravtansine

Why ImmunoGen, Inc. Jumped Higher Today
Motley Fool
Tue, 07/25/17 - 12:01 am
Immunogen
anetumab ravtansine
Bayer
mesothelioma
Bayer misses in mesothelioma Phase 2
BioPharma Dive
Mon, 07/24/17 - 11:05 am
Bayer
mesothelioma
clinical trials
anetumab ravtansine
Bayer’s blockbuster pipeline promises broken by a PhII setback for top cancer drug
Endpoints
Fri, 07/21/17 - 03:12 pm
Bayer
clinical trials
anetumab ravtansine
mesothelioma
Bayer’s Euphoria Around New Cancer Medicine Meets Skepticism
Bloomberg
Tue, 10/18/16 - 09:26 am
Bayer
anetumab ravtansine
cancer